Table of Contents Author Guidelines Submit a Manuscript
Canadian Journal of Infectious Diseases and Medical Microbiology
Volume 2016, Article ID 2478924, 6 pages
http://dx.doi.org/10.1155/2016/2478924
Case Report

Death of a 29-Year-Old Male from Undifferentiated Sepsis

1Queen’s University, Kingston, ON, Canada K7L 3N6
2University of Toronto, Toronto, ON, Canada M5S 1A8
3Department of Pathology and Molecular Medicine, Queen’s University and Kingston General Hospital, Kingston, ON, Canada K7L 3N6
4Department of Family Medicine and Emergency Medicine, Queen’s University, Kingston, ON, Canada K7L 3N6

Received 25 August 2015; Accepted 28 December 2015

Copyright © 2016 Kathryn A. Trebuss et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. P. Dellinger, M. M. Levy, J. M. Carlet et al., “Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008,” Intensive Care Medicine, vol. 34, no. 1, pp. 17–60, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. R. Long and M. Gardam, “Tumour necrosis factor-α inhibitors and the reactivation of latent tuberculosis infection,” Canadian Medical Association Journal, vol. 168, no. 9, pp. 1153–1156, 2003. View at Google Scholar · View at Scopus
  3. “Remicade,” in CPS [Internet], Canadian Pharmacists Association, Toronto, Canada, 2007, http://www.e-therapeutics.ca.
  4. J. Keane, S. Gershon, R. P. Wise et al., “Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent,” The New England Journal of Medicine, vol. 345, no. 15, pp. 1098–1104, 2001. View at Publisher · View at Google Scholar · View at Scopus
  5. G. Murdaca, F. Spanò, M. Contatore et al., “Infection risk associated with anti-TNF-α agents: a review,” Expert Opinion on Drug Safety, vol. 14, no. 4, pp. 571–582, 2015. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Ehlers, “Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept?” Clinical Infectious Diseases, vol. 41, supplement 3, pp. S199–S203, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. M. A. Gardam, E. C. Keystone, R. Menzies et al., “Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management,” Lancet Infectious Diseases, vol. 3, no. 3, pp. 148–155, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. G. R. Baker, P. G. Norton, V. Flintoft et al., “The Canadian Adverse Events Study: the incidence of adverse events among hospital patients in Canada,” Canadian Medical Association Journal, vol. 170, no. 11, pp. 1678–1686, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Vick, C. A. Estrada, and J. M. Rodriguez, “Clinical reasoning for the infectious disease specialist: a primer to recognize cognitive biases,” Clinical Infectious Diseases, vol. 57, no. 4, pp. 573–578, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. B. Andersen and T. Fagerhaug, Root Cause Analysis: Simplified Tools and Techniques, vol. 130, ASQ Quality Press, Milwaukee, Wis, USA, 2000.
  11. P. Croskerry, “From mindless to mindful practice—cognitive bias and clinical decision making,” The New England Journal of Medicine, vol. 368, no. 26, pp. 2445–2448, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Groopman and P. Hartzband, “Thinking about our thinking as physicians,” ACP Internist, October 2011, http://www.acpinternist.org/archives/2011/10/mindful.htm.
  13. MedEffect Canada, Health Canada, December 2015, http://www.hc-sc.gc.ca/dhp-mps/medeff/index_e.html.